Regenxbio Inc (NASDAQ:RGNX) insider Stephen Yoo sold 20,414 shares of the company’s stock in a transaction dated Tuesday, October 16th. The stock was sold at an average price of $60.28, for a total value of $1,230,555.92. Following the completion of the sale, the insider now owns 10,000 shares of the company’s stock, valued at approximately $602,800. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of NASDAQ RGNX traded down $0.37 during mid-day trading on Wednesday, reaching $61.82. The company’s stock had a trading volume of 194,500 shares, compared to its average volume of 547,859. The firm has a market cap of $2.44 billion, a price-to-earnings ratio of -24.83, a price-to-earnings-growth ratio of 15.14 and a beta of -1.19. Regenxbio Inc has a 52 week low of $23.25 and a 52 week high of $85.10.

Regenxbio (NASDAQ:RGNX) last released its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported $0.30 earnings per share for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.93). The business had revenue of $40.03 million during the quarter, compared to the consensus estimate of $100.00 million. Regenxbio had a return on equity of 28.70% and a net margin of 44.44%. On average, sell-side analysts forecast that Regenxbio Inc will post 1.64 earnings per share for the current fiscal year.

RGNX has been the subject of a number of analyst reports. Bank of America cut Regenxbio from a “buy” rating to a “neutral” rating and upped their price target for the stock from $64.00 to $80.00 in a research report on Monday, July 23rd. TheStreet upgraded Regenxbio from a “d+” rating to a “c” rating in a research report on Monday, September 17th. Barclays upped their price target on Regenxbio from $48.00 to $83.00 and gave the stock an “overweight” rating in a research report on Monday, August 13th. Raymond James upped their price target on Regenxbio from $76.00 to $96.00 and gave the stock an “outperform” rating in a research report on Friday, September 7th. Finally, Chardan Capital upped their price target on Regenxbio from $90.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, July 16th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $77.64.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RGNX. BlackRock Inc. boosted its stake in shares of Regenxbio by 89.9% in the second quarter. BlackRock Inc. now owns 4,218,413 shares of the biotechnology company’s stock worth $302,671,000 after acquiring an additional 1,997,447 shares during the period. Marshall Wace LLP bought a new position in shares of Regenxbio in the second quarter worth about $14,712,000. RTW Investments LP boosted its stake in shares of Regenxbio by 10.7% in the second quarter. RTW Investments LP now owns 2,079,555 shares of the biotechnology company’s stock worth $149,208,000 after acquiring an additional 201,788 shares during the period. Voya Investment Management LLC boosted its stake in shares of Regenxbio by 1,514.5% in the second quarter. Voya Investment Management LLC now owns 203,557 shares of the biotechnology company’s stock worth $14,605,000 after acquiring an additional 190,949 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of Regenxbio by 140.6% in the second quarter. Bank of New York Mellon Corp now owns 319,330 shares of the biotechnology company’s stock worth $22,911,000 after acquiring an additional 186,595 shares during the period. 80.81% of the stock is owned by hedge funds and other institutional investors.

About Regenxbio

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Featured Story: Marijuana Stocks Future Looks Bright

Insider Buying and Selling by Quarter for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.